Topline
Drugmaker GSK said Wednesday its RSV vaccine gave long-term protection in older adults after a single shot, according to results from its late stage clinical trial, promising news for efforts to combat the common and potentially lethal infection.
Key Facts
GSK said the shot, which is designed to protect adults ages 60 and older and is marketed as Arexvy, conveyed strong protection against lower respiratory tract disease and severe disease from RSV over two full seasons.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased